The pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories at three dosage strengths and oral syrup were studied. The study had an open-label, randomized ...

Pharmacokinetics is an area of pharmacology concerned with the time course of absorption, distribution, metabolism and excretion (collectively ADME) of drugs from biological systems in order to ...

The pharmacokinetics, safety, and tolerability of four topical lidocaine patches 5% continuously applied for 72 hours and changed every 12 or 24 hours were examined. In this randomized ...

The NMR and Drug Metabolism Core has developed rapid and efficient approaches to investigate metabolism, metabolic stability, pharmacokinetics (PK), and chemical structure identification of small ...

Priority will be given to students with the strongest grades from high-ranking institutions. We expect successful applicants to demonstrate: Interest and basic understanding of pharmacokinetics and ...

Background: There is strong experimental evidence of a neuroprotective effect of melatonin in immature animals. However, pharmacokinetic (PK) data on melatonin in preterm infants is lacking.

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, ...

Adial Pharmaceuticals has completed a pharmacokinetics study of its investigational drug AD04, aimed at treating Alcohol Use Disorder (AUD) in patients with a specific genomic biomarker.

Detailed price information for Y-Mabs Therapeutics Inc (YMAB-Q) from The Globe and Mail including charting and trades.

and used for the simultaneous detection of berberine (BBR), astragaloside IV (AST), and the main metabolites to demonstrate the comparative pharmacokinetics of BBR and AST in normal and T2DM rats.

(RTTNews) - Y-mAbs Therapeutics, Inc. (YMAB), a commercial-stage biopharmaceutical company presented preclinical and translational pharmacokinetics or PK data of GD2-SADA at the 2025 SNMMI Mid ...